GSK plc (LON:GSK) Insider Purchases £19,725 in Stock

GSK plc (LON:GSK - Get Free Report) insider Jonathan Symonds bought 1,500 shares of the business's stock in a transaction dated Friday, December 20th. The shares were bought at an average price of GBX 1,315 ($16.48) per share, with a total value of £19,725 ($24,727.34).

Jonathan Symonds also recently made the following trade(s):

• On Wednesday, October 30th, Jonathan Symonds bought 7,150 shares of GSK stock. The stock was purchased at an average cost of GBX 1,394 ($17.48) per share, for a total transaction of £99,671 ($124,947.98).

GSK Price Performance

GSK traded up GBX 25.50 ($0.32) on Monday, hitting GBX 1,334 ($16.72). 3,698,402 shares of the stock were exchanged, compared to its average volume of 9,962,725. The company has a 50-day moving average of GBX 1,387.25. The firm has a market capitalization of £54.43 billion, a price-to-earnings ratio of 1,180.53, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04. GSK plc has a 12 month low of GBX 1,282.50 ($16.08) and a 12 month high of GBX 1,823.50 ($22.86).

GSK Dividend Announcement

The firm also recently declared a dividend, which will be paid on Thursday, January 9th. Stockholders of record on Thursday, November 14th will be issued a dividend of GBX 15 ($0.19) per share. The ex-dividend date of this dividend is Thursday, November 14th. This represents a dividend yield of 1.03%. GSK's dividend payout ratio (DPR) is currently 5,309.73%.

Analyst Ratings Changes

GSK has been the subject of several research reports. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and set a GBX 1,850 ($23.19) price target on shares of GSK in a report on Tuesday, September 3rd. JPMorgan Chase & Co. reissued an "underweight" rating on shares of GSK in a research report on Wednesday, December 11th. Shore Capital reaffirmed a "buy" rating on shares of GSK in a research report on Wednesday, August 28th. Finally, Berenberg Bank cut their price objective on shares of GSK from GBX 1,820 ($22.82) to GBX 1,600 ($20.06) and set a "buy" rating for the company in a report on Friday, November 29th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of GBX 1,805.83 ($22.64).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.